06618 JD HEALTH
- 27.900
- +1.300+4.89%
JD HEALTH News
JD Health (06618.HK): Three-party merchant ecosystem construction accelerates full coverage of online and offline medical scenarios
JD Health (6618.HK): Gross margin is expected to continue to recover, and service revenue is expected to maintain rapid growth
JD Health (06618.HK) 2023 Annual Report Performance Review: Reducing Costs and Increasing Efficiency to Develop New Quality Productivity Layout Medical Services
JD Health (6618.HK): Expanding the Tripartite Merchant Ecosystem to Help Return to an Endogenous Growth Path
JD Health (6618.HK) 2023 Report Review: The number of merchants on the three sides increased dramatically, and the big model helped reduce costs and increase efficiency
JD Health (6618.HK): Performance growth exceeds expectations, omnichannel business layout accelerates
Nomura Adjusts JD Health's Price Target to HK$44 to HK$37, Keeps at Buy
JD Health (06618.HK): Focus on the impact of a high base on growth performance in 2024 after clearing
Changes in Hong Kong stocks | JD Health (06618) rose more than 7% in the intraday period, institutions are optimistic about the company's revenue prospects, rising earnings estimates and target prices
Bank of America Ratings | Bank of America: Reiterates JD Health's “Buy” Rating Upgrades Last Year's Revenue Forecast
Nomura Adjusts JD Health International's Price Target to HK$44 From HK$60, Keeps at Buy
Changes in Hong Kong stocks | JD Health (06618) rose more than 3%, the health supplement category grew strongly, and institutions raised revenue forecasts and target prices
JD Health (6618.HK): Expecting the return of endogenous growth after the high base effect
JD Health (06618.HK): The number of users continued to grow in 23Q3, focusing on the promotion of omni-channel business layout
JD Health (6618.HK): Active users of the platform continue to grow, and the integrated online and offline layout is progressing steadily
Bank Ratings｜Daimo: First to JD Health's “Sync with the Market” rating target price of HK$43
Changes in Hong Kong stocks | JD Health rose more than 6% and was raised by Goldman Sachs in its target price to HK$76
JD Health (06618.HK): Under a high base, revenue growth rate declined and profit performance was impressive
JD Health (6618.HK): 1H23 reduced costs and increased efficiency significantly, and the company's operating efficiency is expected to continue to improve
JD Health (06618): The number of users continues to grow, operating rates are greatly optimized, and losses are turned into profits
Analysis
Price Target
No Data
